Dexmedetomidine Ropivacaine Versus Plain Ropivacaine in Bilateral Pectoralis Nerve (PECS) Block
Dexmedetomidine Ropivacaine Versus Plain Ropivacaine in Bilateral Pectoralis Nerve (PECS) Block for Fast Tracking and Postoperative Analgesia in Open Heart Surgery Through Midline Sternotomy. A Randomized Clinical Trial
Fayoum University
90 participants
Oct 10, 2024
INTERVENTIONAL
Conditions
Summary
In 2012 Blanco et al. \[1\] described the ultrasound technique for Pectoral nerve (PECS) block as a new, less invasive regional analgesic technique for breast surgeries. PECS block includes PECS I and PECS II (modified PECS I) interfascial blocks. Since that time, PECS block has been used successfully with good results for a wide variety of surgeries on the chest wall such as radical mastectomies, breast-conserving surgeries, breast implant placement, automated implantable cardioverter-defibrillator (AICD)/pacemaker placement, intercostal drainage tube placement, and rib fractures. In this study, the investigators hypothesized that adding dexmedetomidine as an adjuvant to ropivacaine can result in the prolongation of the duration of anesthesia with improvement of the quality of postoperative analgesia of bilateral PECS block for patients undergoing cardiac surgery via midline sternotomy compared with using only plain ropivacaine.
Eligibility
Inclusion Criteria3
- Age 20 - 65 years,
- Ejection fraction (EF) > 35%,
- Elective isolated CABG, or Valve surgery
Exclusion Criteria6
- Poor left ventricular function with intra-aortic balloon pump support,
- Recent myocardial infarction (last seven days),
- Combined procedure (i.e., CABG + other heart/vascular procedure),
- Emergency surgery, or Redo cases,
- Hepatic or renal failure, creatinine >1.5,
- Patients with hemodynamic instability, preexisting infection at the site of block, allergy to local anesthetics, psychiatric illness, and patients with prolonged postoperative ventilatory course were excluded from the study.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
will receive 30 ml of 0.25% of ropivacaine + dexmedetomidine 0.5 μg/kg for each side.
will receive 30 ml of 0.25% of plain ropivacaine for each side.
will not receive any regional anesthesia and only will receive I.V. fentanyl 1μg/kg/hr.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06636578